Cargando…

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer

The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the num...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowak-Sliwinska, Patrycja, Scapozza, Leonardo, Altaba, Ariel Ruiz i
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528778/
https://www.ncbi.nlm.nih.gov/pubmed/31034926
http://dx.doi.org/10.1016/j.bbcan.2019.04.005
_version_ 1783420302765588480
author Nowak-Sliwinska, Patrycja
Scapozza, Leonardo
Altaba, Ariel Ruiz i
author_facet Nowak-Sliwinska, Patrycja
Scapozza, Leonardo
Altaba, Ariel Ruiz i
author_sort Nowak-Sliwinska, Patrycja
collection PubMed
description The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level.
format Online
Article
Text
id pubmed-6528778
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-65287782019-05-28 Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer Nowak-Sliwinska, Patrycja Scapozza, Leonardo Altaba, Ariel Ruiz i Biochim Biophys Acta Rev Cancer Review The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level. Elsevier 2019-04 /pmc/articles/PMC6528778/ /pubmed/31034926 http://dx.doi.org/10.1016/j.bbcan.2019.04.005 Text en © 2019 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Nowak-Sliwinska, Patrycja
Scapozza, Leonardo
Altaba, Ariel Ruiz i
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
title Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
title_full Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
title_fullStr Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
title_full_unstemmed Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
title_short Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
title_sort drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528778/
https://www.ncbi.nlm.nih.gov/pubmed/31034926
http://dx.doi.org/10.1016/j.bbcan.2019.04.005
work_keys_str_mv AT nowaksliwinskapatrycja drugrepurposinginoncologycompoundspathwaysphenotypesandcomputationalapproachesforcolorectalcancer
AT scapozzaleonardo drugrepurposinginoncologycompoundspathwaysphenotypesandcomputationalapproachesforcolorectalcancer
AT altabaarielruizi drugrepurposinginoncologycompoundspathwaysphenotypesandcomputationalapproachesforcolorectalcancer